TGA-approved intranasal esketamine therapy for adults with treatment-resistant depression, delivered under the supervision of experienced psychiatrist and registered nurses.

Spravato (esketamine) is a prescription nasal spray approved by the Therapeutic Goods Administration (TGA) for adults with treatment-resistant depression. Unlike traditional antidepressants, Spravato works through the brain's glutamate system and may provide more rapid symptom relief for suitable patients.

An initial consultation is conducted to assess whether Spravato is an appropriate treatment option for you. Treatment is self-administered in the clinic under direct clinical supervision, followed by a period of observation and monitoring to ensure safety and tolerability.

A GP or specialist referral is required.

For more information, please email esketamine@thepsynapse.com.au.